Preskorn, Sheldon H <br/><br/>
Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.  [electronic resource] 

 -  Journal of psychiatric practice  Sep 2006 
 - 312-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1527-4160 
<br/><br/><label>Standard No.: </label>10.1097/00131746-200609000-00006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anti-HIV Agents--adverse effects<br/>Antidepressive Agents--adverse effects<br/>Antiparkinson Agents--adverse effects<br/>Apomorphine--adverse effects<br/>Atazanavir Sulfate<br/>Azabicyclo Compounds<br/>Carbamates--therapeutic use<br/>Central Nervous System Agents--adverse effects<br/>Cytochrome P-450 Enzyme System--metabolism<br/>Drug Approval--legislation & jurisprudence<br/>Drug Interactions<br/>Duloxetine Hydrochloride<br/>Furans<br/>Humans<br/>Hypnotics and Sedatives--adverse effects<br/>Indenes--adverse effects<br/>Long QT Syndrome--chemically induced<br/>Mental Disorders--drug therapy<br/>Oligopeptides--adverse effects<br/>Organophosphates--therapeutic use<br/>Piperazines--adverse effects<br/>Psychopharmacology--methods<br/>Pyridines--adverse effects<br/>Sulfonamides--therapeutic use<br/>Thiophenes--adverse effects